Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Dihydrolycorine is a natural alkaloid product isolated from the Lycoris radiata plant in the Lycoris genus. As an important member of the lycorine alkaloids, dihydrolycorine has attracted widespread attention in the field of natural product pharmacology in recent years due to its unique chemical structure and significant biological activity. Especially in the treatment research of neurodegenerative diseases, especially Alzheimer's disease (AD), dihydrolycorine has shown potential pharmacological activity and application value.
Alzheimer's disease, as a complex neurodegenerative disease, involves multiple molecular targets such as beta amyloid precursor protein (APP), beta secretase (BACE1), microtubule associated protein Tau (MAPT), alpha synuclein (SNCA), apolipoprotein E (APOE), and precursor protein 1 (PSEN1) in its pathological mechanism. Dihydrolycorine exhibits the potential to inhibit neurodegenerative diseases by regulating the aforementioned targets. In addition, dihydrolycorine, as an inhibitor of protein synthesis in eukaryotic cells, has a unique mechanism of action that provides new ideas for research in neuroprotection and anti-tumor fields.
This article aims to systematically review the chemical structure and physicochemical properties, plant sources and extraction methods, pharmacological activity and mechanism of action, pharmacological evaluation and pharmacokinetic characteristics of dihydrolycorine, as well as its potential prospects and development trends in clinical applications, providing theoretical basis and reference for the in-depth research and drug development of this natural product.
The molecular formula of dihydrolycorine is C16H19NO4, with a molecular weight of 289.3310 and a CAS number of 6271-21-2. Its structure belongs to the lycorine alkaloid class, with a typical indole skeleton. The molecule contains multiple hydroxyl and methoxy substituents, giving it high polarity and biological activity. The LogP value of dihydrolycorine is 0.5220, indicating its moderate lipid solubility, which is beneficial for penetrating cell membranes and the blood-brain barrier (BBB). This characteristic is particularly important for the development of central nervous system drugs.
Its topological polar surface area (TPSA) is 62.16 Å ², indicating that the molecule has a good polarity distribution, which facilitates binding with biological targets. The water solubility is 4.6100, indicating that it has a certain solubility in aqueous phase, which is conducive to absorption and distribution in vivo. Dihydrolycorine does not exhibit hERG channel inhibitory activity, indicating a low risk of cardiac toxicity. The Ames test result is 0.6, indicating a low risk of genotoxicity and meeting safety requirements.
In summary, the physicochemical properties of dihydrolycorine are suitable as the basis for its development as a neurological drug, especially in terms of penetrating the blood-brain barrier and low toxicity.
Dihydrolycorine mainly comes from the Lycoris radiata plant of the Lycoris genus, which is widely distributed in East Asia such as China, Japan, and the Korean Peninsula and has always been used as a traditional herb. Lycoris radiata contains abundant lycorine alkaloids, which are the main natural source of dihydrolycorine.
The common methods for extracting dihydrolycorine include solvent extraction and column chromatography separation. The general steps are as follows: first, the dried aboveground parts or bulbs of Lycoris radiata are crushed, and then extracted with methanol or ethanol. After concentration, impurities are removed using an acid-base aqueous solution separation method. Subsequently, high-purity dihydroallicin was further purified by silica gel column chromatography or high-performance liquid chromatography (HPLC).
In recent years, ultrasound assisted extraction (UAE) and microwave-assisted extraction (MAE) technologies have been introduced into the extraction process of dihydrolycorine, significantly improving extraction efficiency and purity, reducing the use of organic solvents, and complying with the principles of green chemistry. In addition, molecular imprinting technology and membrane separation technology have also been attempted to be applied for efficient separation of this type of alkaloid, promoting its industrial production process.
The study of dihydrolycorine in Alzheimer's disease model shows that it has multi-target regulatory effects. By inhibiting the expression of β - amyloid precursor protein (APP) and β - secretase 1 (BACE1), dihydrolycorine reduced the formation of β - amyloid (A β) plaques and alleviated neurotoxicity. Its regulatory effect on microtubule associated protein Tau (MAPT) helps prevent the formation of neurofibrillary tangles and protect the structural integrity of neurons.
In addition, dihydrolycorine regulates apolipoprotein E (APOE) and precursor proteasome 1 (PSEN1), further improving neuronal metabolism and signal transduction, and slowing down cognitive decline. Its effect on alpha synuclein (SNCA) also suggests that it may play a role in other neurodegenerative diseases such as Parkinson's disease.
As an inhibitor of protein synthesis in eukaryotic cells, dihydrolycorine interferes with ribosome function, inhibits the elongation process of polypeptide chains, and blocks the synthesis of abnormal proteins. This mechanism is not only valued in anti-tumor research, but also provides new explanations for its neuroprotective effects. By reducing the accumulation of abnormal proteins, dihydrolycorine alleviates cellular stress and apoptosis, protecting nerve cells from damage.
In addition to nervous system related activities, dihydrolycorine also exhibits anti-inflammatory, antioxidant, and immunomodulatory effects. It inhibits the release of inflammatory mediators, reduces neuroinflammatory reactions, and further promotes nerve repair. In addition, dihydrolycorine can regulate the activity of oxidative stress-related enzymes and protect cells from free radical damage.
The mechanism of action of dihydrolycorine mainly depends on its regulation of various neurodegenerative disease-related targets:
APP and BACE1 Dihydrolycorine inhibits BACE1 enzyme activity, reduces APP β - cleavage, lowers A β production, alleviates amyloid plaque deposition, and alleviates neurotoxicity.
MAPT (Tau protein)By regulating the phosphorylation status of Tau protein, dihydrolycorine prevents the formation of neurofibrillary tangles, maintains microtubule stability, and promotes normal neuronal function.
SNCA (alpha synuclein)Regulating the expression and aggregation of SNCA, preventing its abnormal deposition, and reducing neuronal damage.
APOE Regulating APOE gene expression, improving lipid metabolism and neuronal repair, and promoting the maintenance of nervous system homeostasis.
PSEN1: Affects the activity of the gamma secretase complex, regulates the APP cleavage pathway, and further affects the generation of A β.
In addition, dihydrolycorine inhibits protein synthesis in eukaryotic cells, reduces the production of abnormal proteins, alleviates intracellular stress responses, and protects nerve cells from apoptosis and necrosis.
The pharmacological parameters of dihydrolycorine indicate that it has good potential for drug development. The molecular weight of 289.33 conforms to Lipinski's rule, and the LogP value of 0.522 indicates a moderate hydrophilic lipophilic balance, which is beneficial for in vivo distribution. The TPSA is 62.16 Å ², indicating that its polarity is moderate and conducive to penetrating the blood-brain barrier, which is in line with the ideal characteristics of central nervous system drugs.
Moderate water solubility (4.61), helpful for oral absorption and bioavailability. The blood-brain barrier has high penetration ability, ensuring its effective targeting of central nervous system targets. HERG channel inhibition is negative, reducing the potential risk of cardiac toxicity. The Ames test results show that its genotoxicity risk is low and its safety is good.
In terms of pharmacokinetics, existing studies have shown that dihydrolycorine is rapidly absorbed after oral administration, with a moderate plasma half-life and the ability to maintain effective concentrations. Its metabolism is mainly through the liver cytochrome P450 enzyme system, and the safety of its metabolites needs further research. The main excretion pathway is through the kidneys, indicating that renal function has a significant impact on its clearance.
Dihydrolycorine, as a natural product with multi-target effects, has shown broad prospects in the treatment of neurodegenerative diseases such as Alzheimer's disease. It has good therapeutic potential by regulating key targets such as APP, BACE1, MAPT, etc., slowing down pathological progression, improving cognitive function.
Future research should focus on in-depth analysis of its mechanism of action, especially the specific effects of signal pathways and protein synthesis inhibition related to neuroprotection. At the same time, systematic pharmacokinetic and toxicological studies need to be conducted to clarify the safe dosage range and long-term application risks.
In addition, by combining modern drug design techniques such as structural optimization and nanocarrier delivery systems, it is expected to enhance the bioavailability and targeting of dihydrolycorine, and improve its clinical efficacy. The implementation of multicenter clinical trials will be a key step in verifying their actual efficacy and safety.
In the context of increasingly urgent research and development of anti Alzheimer's disease drugs, dihydrolycorine, as a natural product with unique advantages, deserves more scientific research resources and clinical attention to promote its transformation from laboratory research to clinical application.
Dihydrolycorine, as an important alkaloid component in Lycoris radiata, has shown significant potential in the fields of anti Alzheimer's disease and neuroprotection due to its unique chemical structure and multi-target pharmacological activity. Its excellent pharmacokinetic parameters and safety features have laid a solid foundation for drug development.
In the future, interdisciplinary research combining modern pharmacology, molecular biology, and medicinal chemistry will further reveal the mechanism of action of dihydrolycorine, optimize its drug properties, and promote its clinical application process. Dihydrolycorine is expected to become a brilliant new star in the natural product drug library, bringing new treatment hope to patients with neurodegenerative diseases.
